

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mega Genomics Limited

美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6667)

DELAY IN DESPATCH OF CIRCULAR

References are made to the announcements of Mega Genomics Limited (the “**Company**”) dated 5 January 2024 and 11 January 2024 in respect of, among other things, the 2024 Meinian OneHealth Genetic Testing Service Framework Agreement and the 2024 Dr. Yu Genetic Testing Service Framework Agreement (“**Announcements**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

As disclosed in Announcements, the Company expected to despatch a circular (the “**Circular**”) in relation to the Agreements on or before 6 February 2024. As more time is required to prepare and finalize the contents of the Circular, the despatch date of the Circular is expected to be postponed to a date on or before 29 February 2024.

By order of the Board
Mega Genomics Limited
LIN Lin

Executive Director and Chairperson

Hong Kong, 6 February 2024

As at the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* *For identification purpose only*